12 June 2018
By Dr Wendy Winnall - PCFA Research Team
Olaparib (Lynparza) is a breast and ovarian cancer drug that is being trialled for prostate cancer patients. Previous trials have shown that men with metastatic castration resistant prostate cancer benefit from Olaparib if they have mutations in DNA repair genes. Exciting results from a newly published trial show that Olaparib works for men without these gene mutations, if the drug is combined with Abiraterone (Zytiga).
To read the full article just log into the PCFA Online Community.
If you're not already a member, it is free and easy to join.
